Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas

NCT02220855 is registered in ClinicalTrials.gov with Patrick Joseph Loehrer Sr. as lead sponsor.

NCT NCT02220855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02220855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Lead sponsor
Patrick Joseph Loehrer Sr.
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2014
Completion date
March 9, 2021
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thymoma